Recombinant Enzyme Fusion Protein for Lysosomal Storage Disorders
用于治疗溶酶体贮积症的重组酶融合蛋白
基本信息
- 批准号:7413300
- 负责人:
- 金额:$ 45.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAffinityAffinity ChromatographyAnimal ModelAnionsAntibodiesBeta-glucuronidaseBindingBiological AssayBioreactorsBlood - brain barrier anatomyBlood VesselsBlood capillariesBrainBrain PartBypassCOS CellsCanis familiarisCarbohydratesCationsCellsCephalicCessation of lifeChildChimeric ProteinsChinese Hamster Ovary CellChromatographyClinical TrialsCloningComplementary DNAConditionConditioned Culture MediaContractsDNA Restriction EnzymesDNA Sequence AnalysisDermatan SulfateDevelopmentDihydrofolate ReductaseDiseaseDoseDrug KineticsElectroporationEngineeringEnzyme-Linked Immunosorbent AssayEnzymesEquus caballusFiltrationFutureGenesGenetic EngineeringGlucuronidesGoalsGrantGuanosine MonophosphateHeparitin SulfateHereditary DiseaseHistamineHumanHydrolysisImmunoglobulin GInborn Errors of MetabolismInjection of therapeutic agentInstitutionInsulin ReceptorIsoelectric FocusingLaboratoriesLegal patentLightLiverMacaca mulattaMass Spectrum AnalysisMeasuresMediatingMethodsMethotrexateModelingMolecular Sieve ChromatographyMolecular WeightMonoclonal AntibodiesMucopolysaccharidosis VIIMusMutateNeuraxisOrganOrphan DrugsOutsourcingPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacology and ToxicologyPhasePhase II Clinical TrialsPhase III Clinical TrialsPlasmidsPolyacrylamide Gel ElectrophoresisPolymerase Chain ReactionPreparationPrimatesProcessProductionProtein EngineeringProteinsRadiolabeledRecombinant AntibodyRecombinant Fusion ProteinsRecombinant ProteinsRecombinantsResearchRodentRunningSerumSmall Business Funding MechanismsSmall Business Innovation Research GrantSodium Dodecyl SulfateSolutionsSpinal CordStagingStructureSystemTechnologyTestingTherapeuticTherapeutic EffectTransfectionUnited States Food and Drug AdministrationWestern BlottingWorkabstractingbrain cellcapillarycell bankchimeric antibodycommercializationdaltondesignenzyme activityenzyme replacement therapyexpression vectorfusion geneglucuronidehuman INSR proteinin vivointravenous administrationintravenous injectionlysosomal glycosyl hydrolasemilligrammolecular trojan horsenovelnovel strategiespeptide permeasepreclinical studyprogressive neurodegenerationprototyperadiotracerreceptorreceptor bindingsizesmall moleculetherapeutic enzymetranscytosisuptakevector
项目摘要
DESCRIPTION (provided by applicant): Zhang, Yun Abstract There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment is enzyme replacement therapy (ERT). However, ERT is not effective for the brain, because the enzymes do not cross the brain capillary wall, which forms the blood-brain barrier (BBB) in vivo. Without treatment of the CNS, the young patients are destined to progressive neurodegeneration and death. The limiting factor in the future treatment of these diseases is the transport of the enzyme across the BBB. Bypass of the BBB with direct injection into the brain is not effective, because only a small part of the brain is treated with a trans-cranial delivery system. Conversely, virtually all cells of the brain can be treated with a trans-vascular delivery system that enables the enzyme to cross the BBB following intravenous administration. A new approach to the BBB delivery of large molecules such as enzymes is the molecular Trojan horse technology. A bi-functional fusion protein is produced with genetic engineering, wherein the missing recombinant enzyme is fused to a BBB molecular Trojan horse. The latter is a genetically engineered protein that is able to cross the human BBB by receptor- mediated transcytosis on endogenous BBB peptide transport systems. Pre-clinical studies show that a large enzyme with a molecular weight >100,000 Daltons, can be delivered to brain via transport across the BBB, following attachment to a BBB receptor-specific Trojan horse. The present work will produce a novel fusion gene encoding a lysosomal enzyme and a genetically engineered molecular Trojan horse, which will allow the production of the corresponding fusion protein, AGT-180. The fusion gene will be incorporated in a eukaryotic expression vector followed by permanent transfection of cells. These phase II studies will enable production of a master cell bank and development of the purification and downstream processing of the fusion protein. Fusion proteins comprised of BBB targeting antibodies and recombinant enzymes could be therapeutic in the treatment of the brain in human lysosomal storage disorders. 1 Zhang, Yun Project Narrative Lysosomal storage disorders are serious inborn errors of metabolism, and about 75% of the ~40 lysosomal storage disorders affect the brain. The mainstay of treatment is Enzyme Replacement Therapy (ERT). However, ERT is ineffective in the brain, because the enzymes do not cross the blood-brain barrier (BBB). The present work will produce a novel recombinant fusion protein that is able to both (a) bind a human BBB receptor to trigger transport into the brain, and (b) retain high lysosomal enzyme activity. This novel drug, designated AGT-180, will be a model for the treatment of the brain for multiple genetic diseases. 1
描述(申请人提供): 张云 摘要 溶酶体贮积症有 40 多种,其中大多数疾病对中枢神经系统(CNS)产生不利影响。主要治疗方法是酶替代疗法(ERT)。然而,ERT 对大脑无效,因为酶不能穿过脑毛细血管壁,而脑毛细血管壁在体内形成血脑屏障 (BBB)。如果不治疗中枢神经系统,年轻患者注定会出现进行性神经退行性病变和死亡。未来治疗这些疾病的限制因素是酶穿过血脑屏障的运输。绕过血脑屏障直接注射到大脑中的方法并不有效,因为只有一小部分大脑接受了经颅给药系统的治疗。相反,几乎所有大脑细胞都可以通过跨血管递送系统进行治疗,该系统使酶能够在静脉注射后穿过血脑屏障。一种通过血脑屏障传递酶等大分子的新方法是分子特洛伊木马技术。通过基因工程产生双功能融合蛋白,其中缺失的重组酶与BBB分子特洛伊木马融合。后者是一种基因工程蛋白,能够通过内源性 BBB 肽转运系统上受体介导的转胞吞作用穿过人类 BBB。临床前研究表明,分子量 >100,000 道尔顿的大酶在附着于 BBB 受体特异性特洛伊木马后,可以通过 BBB 运输输送到大脑。目前的工作将产生一种编码溶酶体酶的新型融合基因和一个基因工程分子特洛伊木马,这将允许产生相应的融合蛋白AGT-180。融合基因将被整合到真核表达载体中,然后永久转染细胞。这些第二阶段研究将能够生产主细胞库并开发融合蛋白的纯化和下游加工。由 BBB 靶向抗体和重组酶组成的融合蛋白可用于治疗人类溶酶体贮积症的大脑。 1 张云项目叙述溶酶体贮积症是严重的先天性代谢错误,约 40 种溶酶体贮积症中约 75% 影响大脑。主要治疗方法是酶替代疗法(ERT)。然而,ERT 在大脑中无效,因为酶不能穿过血脑屏障 (BBB)。目前的工作将产生一种新型重组融合蛋白,它能够(a)结合人类 BBB 受体以触发转运到大脑中,并且(b)保留高溶酶体酶活性。这种新药被命名为 AGT-180,将成为治疗大脑多种遗传性疾病的模型。 1
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genetic engineering of IgG-glucuronidase fusion proteins.
- DOI:10.3109/10611860903353362
- 发表时间:2010-04
- 期刊:
- 影响因子:4.5
- 作者:Boado RJ;Pardridge WM
- 通讯作者:Pardridge WM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUN ZHANG其他文献
YUN ZHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUN ZHANG', 18)}}的其他基金
Bioengineering of a New Antibody Drug Delivery Technology
新型抗体药物递送技术的生物工程
- 批准号:
7476113 - 财政年份:2008
- 资助金额:
$ 45.66万 - 项目类别:
Recombinant Enzyme Fusion Protein for Lysosomal Storage Disorders
用于治疗溶酶体贮积症的重组酶融合蛋白
- 批准号:
7218543 - 财政年份:2007
- 资助金额:
$ 45.66万 - 项目类别:
Recombinant Enzyme Fusion Protein for Lysosomal Storage
用于溶酶体储存的重组酶融合蛋白
- 批准号:
7049235 - 财政年份:2006
- 资助金额:
$ 45.66万 - 项目类别:
Imaging Brain Amyloid with a Bispecific Antibody
使用双特异性抗体对脑淀粉样蛋白进行成像
- 批准号:
6929525 - 财政年份:2005
- 资助金额:
$ 45.66万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 45.66万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 45.66万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 45.66万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 45.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




